Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives

References

• Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–22. doi:10.1053/j.gastro.2017.04.022
   PubMed Web of Science ®Google Scholar
• Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093–2112. doi:10.1136/gutjnl-2020-322368. PMCID: 33004546.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. doi:10.1136/gutjnl-2016-312288. PMCID: 27707777.
   PubMed Web of Science ®Google Scholar
• Ying L, Ferrero RL. Role of NOD1 and ALPK1/TIFA Signalling in Innate Immunity Against Helicobacter pylori Infection. Curr Top Microbiol Immunol. 2019;421:159–177.
   PubMed Web of Science ®Google Scholar
• Robinson K, Atherton JC. The Spectrum of Helicobacter-Mediated Diseases. Annu Rev Pathol. 2021;16:123–144.
   PubMed Web of Science ®Google Scholar
• Cai Q, Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y, Li J, Zhang K, Ye G, Ye L, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut. 2019;68(9):1576–1587. doi:10.1136/gutjnl-2018-317556. PMCID: 30926654.
   PubMed Web of Science ®Google Scholar
• Queiroz DM, Harris PR, Sanderson IR, Windle HJ, Walker MM, Rocha AM, Rocha GA, Carvalho SD, Bittencourt PF, de Castro LP, et al. Iron status and Helicobacter pylori infection in symptomatic children: an international multi-centered study. PloS one. 2013;8(7):e68833. doi:10.1371/journal.pone.0068833. PMCID: 23861946.
   PubMed Web of Science ®Google Scholar
• Sato R, Murakami K, Okimoto T, Watanabe K, Kodama M, Fujioka T. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol. 2011;46:991–997.
   PubMed Web of Science ®Google Scholar
• Green R, Allen LH, Bjørke-Monsen AL, Brito A, Guéant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, et al. Vitamin B(12) deficiency. Nat Rev Dis Primers. 2017;3:17040 doi:10.1038/nrdp.2017.40. PMCID: 28660890.
   PubMed Web of Science ®Google Scholar
• Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi:10.1136/gutjnl-2015-309252
   PubMed Web of Science ®Google Scholar
• Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113–2121. doi:10.1136/gutjnl-2020-320839
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–239. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16(9):1353–1367. doi:10.1080/14787210.2018.1511427
   Web of Science ®Google Scholar
• Howden CW, Graham DY. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021;116:1–3.
   PubMed Web of Science ®Google Scholar
• Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18:613–629.
   PubMed Web of Science ®Google Scholar
• Capurro MI, Greenfield LK, Prashar A, Xia S, Abdullah M, Wong H, Zhong XZ, Bertaux-Skeirik N, Chakrabarti J, Siddiqui I, et al. VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1. Natu microbiol. 2019;4(8):1411–1423. doi:10.1038/s41564-019-0441-6. PMCID: 31110360.
   PubMed Web of Science ®Google Scholar
• Chouhan D, Mandal BB. Silk biomaterials in wound healing and skin regeneration therapeutics: from bench to bedside. Acta biomaterialia. 2020;103:24–51.
   PubMed Web of Science ®Google Scholar
• Kharaziha M, Baidya A, Annabi N. Rational design of immunomodulatory hydrogels for chronic wound healing. Adv Mater. 2021;33:e2100176.
   PubMed Web of Science ®Google Scholar
• Xu W, Dong S, Han Y, Li S, Liu Y. Hydrogels as antibacterial biomaterials. Curr Pharm Des. 2018;24:843–854.
   PubMed Web of Science ®Google Scholar
• Pan H, Zheng M, Ma A, Liu L, Cai L. Cell/bacteria-based bioactive materials for cancer immune modulation and precision therapy. Adv Mater. 2021;33:e2100241.
   PubMed Web of Science ®Google Scholar
• de Souza MPC, de Camargo BAF, Spósito L, Fortunato GC, Carvalho GC, Marena GD, Meneguin AB, Bauab TM, Chorilli M, et al. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections. Crit Rev Microbiol. 2021;47(4):435–460. doi:10.1080/1040841x.2021.1895721. PMCID: 33725462.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Masanam E, Ramkumar VS, Baskaraligam V, Selvaraj G. Influence of N-acylhomoserine lactonase silver nanoparticles on the quorum sensing system of Helicobacter pylori: a potential strategy to combat biofilm formation. J Basic Microbiol. 2020;60:207–215.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhou Y, Fan Y, Cao R, Xu Y, Weng Z, Ye J, He C, Zhu Y, Wang X. Metal-organic-framework-based hydrogen-release platform for multieffective Helicobacter pylori targeting therapy and intestinal flora protective capabilities. Adv Mater. 2022;34(2):e2105738. doi:10.1002/adma.202105738. PMCID: 34655499.
   PubMed Web of Science ®Google Scholar
• Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm. 2012;9:2677–2685.
   PubMed Web of Science ®Google Scholar
• Zhi X, Liu Y, Lin L, Yang M, Zhang L, Zhang L, Liu Y, Alfranca G, Ma L, Zhang Q, et al. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome. Nanomedicine. 2019;20:102019. doi:10.1016/j.nano.2019.102019. PMCID: 31125676.
   PubMed Web of Science ®Google Scholar
• Saravanakumar K, Chelliah R, MubarakAli D, Oh DH, Kathiresan K, Wang MH. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori. Sci Rep. 2019;9:5787.
   PubMed Web of Science ®Google Scholar
• Lin J, Huang WW. A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. World J Gastroenterol. 2009;15:4715–4719.
   PubMed Web of Science ®Google Scholar
• Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21:10644–10653.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu WK, Gallo RL, Fang EF, Hu W, Ling TK, Shen J, Chan RL, Lu L, Luo XM, et al. Critical role of antimicrobial peptide cathelicidin for controlling Helicobacter pylori survival and infection. J Immunol. 2016;196(4):1799–1809. doi:10.4049/jimmunol.1500021. PMCID: 26800870.
   PubMed Web of Science ®Google Scholar
• Ni WW, Liu Q, Ren SZ, Li WY, Yi LL, Jing H, Sheng LX, Wan Q, Zhong PF, Fang HL, et al. The synthesis and evaluation of phenoxyacylhydroxamic acids as potential agents for Helicobacter pylori infections. Bioorg Med Chem. 2018;26(14):4145–4152. doi:10.1016/j.bmc.2018.07.003. PMCID: 29983280.
   PubMed Web of Science ®Google Scholar
• Robinson K, Lehours P. Review - Helicobacter, inflammation, immunology and vaccines. Helicobacter. 2020;25:e12737.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine. 2020;15:527–542.
   PubMed Web of Science ®Google Scholar
• Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Rev Anti Infect Ther. 2019;17:829–840.
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.
   PubMed Web of Science ®Google Scholar
• Fang JY, Du YQ, Liu WZ, Ren JL, Li YQ, Chen XY, Lv NH, Chen YX, Lv B. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis. 2018;19(4):182–203. doi:10.1111/1751-2980.12593. PMCID: 29573173.
   PubMed Web of Science ®Google Scholar
• Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther. 2014;14:947–954.
   PubMed Web of Science ®Google Scholar
• Sukri A, Hanafiah A, Mohamad Zin N, Kosai NR. Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. APMIS. 2020;128:150–161.
   PubMed Web of Science ®Google Scholar
• Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, ChuangSL, Shieh CF, Liu CY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243–250. doi:10.1136/gutjnl-2020-322200. PMCID: 32792335.
   PubMed Web of Science ®Google Scholar
• Ansari S, Yamaoka Y. Helicobacter pylori Virulence factors exploiting gastric colonization and its pathogenicity. Toxins. 2019;11(11):14–23.
   PubMed Web of Science ®Google Scholar
• Baj J, Forma A, Sitarz M, et al. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2020;10(1):e00001
   PubMed Web of Science ®Google Scholar
• Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14–23.
   PubMed Web of Science ®Google Scholar
• Xu C, Soyfoo DM, Wu Y, Xu S. Virulence of Helicobacter pylori outer membrane proteins: an updated review. EurJ Clin Microbiol Infect Dis. 2020;39:1821–1830.
   PubMed Web of Science ®Google Scholar
• Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53:33–50.
   PubMed Web of Science ®Google Scholar
• Cover TL, Lacy DB, Ohi MD. The Helicobacter pylori cag type IV secretion system. Trends Microbiol. 2020;28:682–695.
   PubMed Web of Science ®Google Scholar
• Xie C, Li N, Wang H, He C, Hu Y, Peng C, Ouyang Y, Wang D, Xie Y, Chen J, et al. Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to H. pylori infection. Gut Microbes. 2020;11(6):1567–1589. doi:10.1080/19490976.2020.1774311. PMCID: 32588736.
   PubMed Web of Science ®Google Scholar
• Raju D, Hussey S, Ang M, Terebiznik MR, Sibony M, Galindo-Mata E, Gupta V, Blanke SR, Delgado A, Romero-Gallo J, et al. Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans. Gastroenterology. 2012;142(5):1160–1171. doi:10.1053/j.gastro.2012.01.043. PMCID: 22333951.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol. 2021;14:17562848211064080.
   Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–1026. doi:10.1136/gutjnl-2019-319954. PMCID: 31915235.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J. 2020;133:335–343.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Lee H, Lee YC, Jeon SW, Kim JH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, et al. Ten-day concomitant, 10-day sequential, and 7-day triple therapy as first-line treatment for Helicobacter pylori Infection: a nationwide randomized Trial in Korea. Gut Liver. 2019;13(5):531–540. doi:10.5009/gnl19136. PMCID: 31505907.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol. 2015;21:12954–12962.
   PubMed Web of Science ®Google Scholar
• Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut. 2022;71:643–650.
   PubMed Web of Science ®Google Scholar
• Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: a Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020;172:795–802.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36:1159–1163.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446.
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718–1724. doi:10.1093/jac/dkz046. PMCID: 30768161.
   PubMed Web of Science ®Google Scholar
• Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, Ikehara H, Gotoda T. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36(12):3314–3321. doi:10.1111/jgh.15572. PMCID: 34107551.
   PubMed Web of Science ®Google Scholar
• Du YQ, Su T, Fan JG, Lu YH, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012;18(43):6302–6307. doi:10.3748/wjg.v18.i43.6302. PMCID: 23180952.
   PubMed Web of Science ®Google Scholar
• Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, et al. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 Edition). Gut. 2022;71(2):238–253. doi:10.1136/gutjnl-2021-325630. PMCID: 34836916.
   PubMed Web of Science ®Google Scholar
• Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. doi:10.1136/bmj.h4052. PMCID: 26290044.
   PubMed Web of Science ®Google Scholar
• Yonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and Its Involvement for Antibiotic Resistance. Biomed Res Int. 2015;2015:914791.
   PubMed Web of Science ®Google Scholar
• Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori biofilm formation and its potential role in pathogenesis. Microbiol Mol Biol Rev. 2018;82(2):e00001–18
   PubMed Web of Science ®Google Scholar
• Moghadam MT, Chegini Z, Khoshbayan A, Farahani I, Shariati A. Helicobacter pylori Biofilm and New Strategies to Combat it. Curr Mol Med. 2021;21:549–561.
   PubMed Web of Science ®Google Scholar
• Patil-Sen Y. Advances in nano-biomaterials and their applications in biomedicine. Emerg Top Life Sci. 2021;5:169–176.
   PubMedGoogle Scholar
• Pinilla CMB, Lopes NA, Brandelli A. Lipid-based nanostructures for the delivery of natural antimicrobials. Molecules. 2021;26(12):3587
   PubMed Web of Science ®Google Scholar
• Yousefi M, Ehsani A, Jafari SM. Lipid-based nano delivery of antimicrobials to control food-borne bacteria. Adv Colloid Interface Sci. 2019;270:263–277.
   PubMed Web of Science ®Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5:305–313.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie F, Yin Y, Zhang Q, Jin H, Wu Y, Pang L, Li J, Gao J. Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma. Int J Nanomedicine. 2021;16:1553–1564. doi:10.2147/ijn.s291421. PMCID:33658783.
   PubMed Web of Science ®Google Scholar
• Li M, Du C, Guo N, Teng Y, Meng X, Sun H, Li S, Yu P, Galons H. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–653. doi:10.1016/j.ejmech.2019.01.007. PMCID: 30640028.
   PubMed Web of Science ®Google Scholar
• Eleraky NE, Allam A, Hassan SB, Omar MM. Nanomedicine Fight against Antibacterial Resistance: an Overview of the Recent Pharmaceutical Innovations. Pharmaceutics. 2020;12(2):8271–85.
   Web of Science ®Google Scholar
• Dai D, Yin Y, Hu Y, Lu Y, Zou H, Lu G, WangLian QJ, Gao J, Shen X. Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer. Drug Deliv. 2021;28(1):1548–1561. doi:10.1080/10717544.2021.1954727. PMCID: 34286631.
   PubMed Web of Science ®Google Scholar
• Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics. 2016;6:1336–1352.
   PubMed Web of Science ®Google Scholar
• Plaza-Oliver M, Santander-Ortega MJ, Lozano MV. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. 2021;11:471–497.
   PubMed Web of Science ®Google Scholar
• Alam MI, Paget T, Elkordy AA. Formulation and advantages of furazolidone in liposomal drug delivery systems. Europ j pharm sci. 2016;84:139–145.
   PubMed Web of Science ®Google Scholar
• Thamphiwatana S, Gao W, Pornpattananangkul D, Zhang Q, Fu V, Li J, Li J, Obonyo M, Zhang L. Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Mater Chem B. 2014;2(46):8201–8207. doi:10.1039/c4tb01110d. PMCID: 25544886.
   PubMed Web of Science ®Google Scholar
• Gottesmann M, Goycoolea FM, Steinbacher T, Menogni T, Hensel A. Smart drug delivery against Helicobacter pylori: pectin-coated, mucoadhesive liposomes with antiadhesive activity and antibiotic cargo. Appl Microbiol Biotechnol. 2020;104:5943–5957.
   PubMed Web of Science ®Google Scholar
• Bardonnet PL, Faivre V, Boullanger P, Piffaretti JC, Falson F. Pre-formulation of liposomes against Helicobacter pylori: characterization and interaction with the bacteria. Eur J Pharm Biopharm. 2008;69:908–922.
   PubMed Web of Science ®Google Scholar
• Cai J, Huang H, Song W, Hu H, Chen J, Zhang L, Li P, Wu R, Wu C. Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharm. 2015;495(2):728–737. doi:10.1016/j.ijpharm.2015.09.055. PMCID: 26417849.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen L, Sun HW, Guo H, Song Z, You Y, Yang LY, Tong YN, Gao JN, Zeng H, et al. Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. J Nanobiotechnology. 2019;17(1):6. doi:10.1186/s12951-019-0441-y. PMCID: 30660182.
   PubMedGoogle Scholar
• Seabra CL, Nunes C, Brás M, Gomez-Lazaro M, Reis CA, Gonçalves IC, Reis S, Martins MCL. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota. Eur J Pharm Biopharm. 2018;127:378–386. doi:10.1016/j.ejpb.2018.02.030. PMCID: 29524597.
   PubMed Web of Science ®Google Scholar
• Thamphiwatana S, Gao W, Obonyo M, Zhang L. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A. 2014;111:17600–17605.
   PubMed Web of Science ®Google Scholar
• Wang R, Song C, Gao A, Liu Q, Guan W, Mei J, Ma L, Cui D. Antibody-conjugated liposomes loaded with indocyanine green for oral targeted photoacoustic imaging-guided sonodynamic therapy of Helicobacter pylori infection. Acta biomaterialia. 2022. doi:10.1016/j.actbio.2022.02.031.
   Google Scholar
• Singh DY, Prasad NK. Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections. Die Pharmazie. 2011;66:368–373.
   PubMed Web of Science ®Google Scholar
• Jain P, Jain S, Prasad KN, Jain SK, Vyas SP. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection. Mol Pharm. 2009;6:593–603.
   PubMedGoogle Scholar
• Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154-155:102–122.
   PubMed Web of Science ®Google Scholar
• Vargas KM, Shon YS. Hybrid lipid-nanoparticle complexes for biomedical applications. J Mater Chem B. 2019;7:695–708.
   PubMed Web of Science ®Google Scholar
• Tran LTC, Gueutin C, Frebourg G, Burucoa C, Faivre V. Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: protection and synergy. Biochem Biophys Res Commun. 2017;493:146–151.
   PubMed Web of Science ®Google Scholar
• Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613.
   PubMed Web of Science ®Google Scholar
• Seabra CL, Nunes C, Gomez-Lazaro M, Correia M, Machado JC, Gonçalves IC, Reis CA, Reis S, Martins MCL. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. Int J Pharm. 2017;519(1–2):128–137 doi:10.1016/j.ijpharm.2017.01.014. PMCID: 28088639.
   PubMed Web of Science ®Google Scholar
• Mirchandani Y, Patravale VB, B S. Solid lipid nanoparticles for hydrophilic drugs. J Control Release. 2021;335:457–464.
   PubMed Web of Science ®Google Scholar
• Borandeh S, van Bochove B, Teotia A, Seppälä J. Polymeric drug delivery systems by additive manufacturing. Adv Drug Deliv Rev. 2021;173:349–373.
   PubMed Web of Science ®Google Scholar
• Zhang S, Li Y, Qiu X, Jiao A, Luo W, Lin X, Zhang X, Zhang Z, Hong J, Cai P, et al. Incorporating redox-sensitive nanogels into bioabsorbable nanofibrous membrane to acquire ROS-balance capacity for skin regeneration. Bioact Mater. 2021;6(10):3461–3472. doi:10.1016/j.bioactmat.2021.03.009. PMCID: 33817421.
   PubMed Web of Science ®Google Scholar
• Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacoll Rep. 2012;64:1020–1037.
   PubMed Web of Science ®Google Scholar
• Luo D, Guo J, Wang F, Sun J, Li J, Cheng X, Chang M, Yan X. Preparation and evaluation of anti-Helicobacter pylori efficacy of chitosan nanoparticles in vitro and in vivo. J Biomater Sci Polym Ed. 2009;20(11):1587–1596. doi:10.1163/092050609x12464345137685. PMCID: 19619399.
   PubMed Web of Science ®Google Scholar
• Yang SJ, Huang CH, Yang JC, Wang CH, Shieh MJ. Residence time-extended nanoparticles by magnetic field improve the eradication efficiency of Helicobacter pylori. ACS Appl Mater Interfaces. 2020;12:54316–54327.
   PubMed Web of Science ®Google Scholar
• Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials. 2013;34:4466–4479.
   PubMed Web of Science ®Google Scholar
• Lin YH, Chang CH, Wu YS, Hsu YM, Chiou SF, Chen YJ. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials. 2009;30:3332–3342.
   PubMed Web of Science ®Google Scholar
• Li P, Chen X, Shen Y, Li H, Zou Y, Yuan G, Hu P, Hu H. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019;300:52–63. doi:10.1016/j.jconrel.2019.02.039. PMCID: 30825476.
   PubMed Web of Science ®Google Scholar
• Lin YH, Lin JH, Chou SC, Chang SJ, Chung CC, Chen YS, Chang CH. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine. 2015;10(1):57–71. doi:10.2217/nnm.14.76. PMCID: 25177920.
   PubMed Web of Science ®Google Scholar
• Arif M, Sharaf M, Samreen K, Chi S, Liu Z. Chitosan-based nanoparticles as delivery-carrier for promising antimicrobial glycolipid biosurfactant to improve the eradication rate of Helicobacter pylori biofilm. J Biomater Sci Polym Ed. 2021;32:813–832.
   PubMed Web of Science ®Google Scholar
• Pan-In P, Banlunara W, Chaichanawongsaroj N, Wanichwecharungruang S. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. Carbohydr Polym. 2014;109:22–27. doi:10.1016/j.carbpol.2014.03.025
   PubMed Web of Science ®Google Scholar
• Pippa N, Gazouli M, Pispas S. Recent advances and future perspectives in polymer-based nanovaccines. Vaccines. 2021;9(6):558. doi:10.3390/vaccines9060558
   Web of Science ®Google Scholar
• Chehelgerdi M, Doosti A. Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine. J Nanobiotechnology. 2020;18(1):63. doi:10.1186/s12951-020-00618-1
   PubMed Web of Science ®Google Scholar
• Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Eur J Pharm Biopharm. 2017;111:33–43. doi:10.1016/j.ejpb.2016.11.007
   PubMed Web of Science ®Google Scholar
• Song H, Lv X, Yang J, Liu W, Yang H, Xi T, Xing Y. A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model. Appl Microbiol Biotechnol. 2015;99(22):9495–9502. doi:10.1007/s00253-015-6705-z
   PubMed Web of Science ®Google Scholar
• Fallen MJ, Clayton CL. Vaccination against Helicobacter pylori urease. Lancet. 1990;336(8708):186–187. doi:10.1016/0140-6736(90)91716-N
   Web of Science ®Google Scholar
• Sutton P, Chionh YT. Why can’t we make an effective vaccine against Helicobacter pylori ? Expert Rev Vaccines. 2013;12(4):433–441. doi:10.1586/erv.13.20
   PubMed Web of Science ®Google Scholar
• Milani M, Sharifi Y, Rahmati-Yamchi M, Somi MH, Akbarzadeh A. Immunology and vaccines and nanovaccines for Helicobacter pylori infection. Expert Rev Vaccines. 2015;14(6):833–840. doi:10.1586/14760584.2015.1008460
   PubMed Web of Science ®Google Scholar
• Arif M. Complete life of cobalt nanoparticles loaded into cross-linked organic polymers: a review. RSC Adv. 2022;12(24):15447–15460. doi:10.1039/D2RA01058E
   PubMed Web of Science ®Google Scholar
• Zaidi S, Misba L, Khan AU. Nano-therapeutics: a revolution in infection control in post antibiotic era. Nanomedicine: Nanotechnology, Biology and Medicine. 2017;13(7):2281–2301. doi:10.1016/j.nano.2017.06.015
   PubMed Web of Science ®Google Scholar
• Almeida Furquim de Camargo B, Soares Silva DE, Noronha da Silva A, Campos DL, Machado Ribeiro TR, Mieli MJ, Borges Teixeira Zanatta M, Bento da Silva P, Pavan FR, Gallina Moreira C, et al. New Silver(I) coordination compound loaded into polymeric nanoparticles as a strategy to improve in vitro Anti- Helicobacter pylori Activity. Mol Pharm. 2020;17(7):2287–2298. doi:10.1021/acs.molpharmaceut.9b01264
   PubMedGoogle Scholar
• Thamphiwatana S, Fu V, Zhu J, Lu D, Gao W, Zhang L. Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery. Langmuir. 2013;29(39):12228–12233. doi:10.1021/la402695c
   PubMed Web of Science ®Google Scholar
• Shahid M, Farooqi ZH, Begum R, Arif M, Wu W, Irfan A. Hybrid microgels for catalytic and photocatalytic removal of nitroarenes and organic dyes from aqueous medium: a review. Crit Rev Anal Chem. 2020;50(6):513–537. doi:10.1080/10408347.2019.1663148
   PubMed Web of Science ®Google Scholar
• Arif M, Farooqi ZH, Irfan A, Begum R. Gold nanoparticles and polymer microgels: last five years of their happy and successful marriage. J Mol Liq. 2021;336:116270. doi:10.1016/j.molliq.2021.116270
   Web of Science ®Google Scholar
• Lin Z, Gao C, Wang D, He Q. Bubble-Propelled janus gallium/zinc micromotors for the active treatment of bacterial infections. Angewandte Chemie International Edition. 2021;60(16):8750–8754. doi:10.1002/anie.202016260
   PubMed Web of Science ®Google Scholar
• Saravanan M, Gopinath V, Chaurasia MK, Syed A, Ameen F, Purushothaman N. Green synthesis of anisotropic zinc oxide nanoparticles with antibacterial and cytofriendly properties. Microb Pathog. 2018;115:57–63. doi:10.1016/j.micpath.2017.12.039
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Bhattacharya S, Chowdhury R, Chakrabarti P, Webber MA. The molecular basis of inactivation of metronidazole-resistant Helicobacter pylori using polyethyleneimine functionalized zinc oxide nanoparticles. PloS one. 2013;8(8):e70776. doi:10.1371/journal.pone.0070776
   PubMed Web of Science ®Google Scholar
• Bhoyar PK, Morani DO, Biyani DM, Umekar MJ, Mahure JG, Amgaonkar YM. Encapsulation of naproxen in lipid-based matrix microspheres: characterization and release kinetics. J youn pharmac. 2011;3(2):105–111. doi:10.4103/0975-1483.80293
   PubMedGoogle Scholar
• Jóhannesson G, Stefánsson E, Loftsson T. Microspheres and nanotechnology for drug delivery. Dev Ophthalmol. 2016;55:93–103.
   PubMedGoogle Scholar
• Uyen NTT, Hamid ZAA, Tram NXT, Ahmad N. Fabrication of alginate microspheres for drug delivery: a review. Int J Biol Macromol. 2020;153:1035–1046. doi:10.1016/j.ijbiomac.2019.10.233
   PubMed Web of Science ®Google Scholar
• Tripathi GK, Singh S, Nath G, Dubey RK. Evaluation of pH triggers in situ porous controlled release micro balloon delivery of amoxicillin for eradication of Helicobacter pylori. <![CDATA[Current Drug Delivery]]>. 2011;8(6):667–677. doi:10.2174/156720111797635531
   PubMed Web of Science ®Google Scholar
• Zheng KK, Tong Y, Zhang SH, He R, Xiao L, Iqbal Z, Zhang Y, Gao J, Zhang L, Jiang L, et al. Flexible bicolorimetric polyacrylamide/chitosan hydrogels for smart real-time monitoring and promotion of wound healing. Adv Funct Mater. 2021;31(34):2102599. doi:10.1002/adfm.202102599
   Web of Science ®Google Scholar
• Gonçalves IC, Magalhães A, Fernandes M, Rodrigues IV, Reis CA, Martins MC. Bacterial-binding chitosan microspheres for gastric infection treatment and prevention. Acta biomaterialia. 2013;9(12):9370–9378. doi:10.1016/j.actbio.2013.07.034
   PubMed Web of Science ®Google Scholar
• Adebisi AO, Conway BR. Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. Int J Pharm. 2014;470(1–2):28–40. doi:10.1016/j.ijpharm.2014.04.070
   PubMedGoogle Scholar
• Gonçalves IC, Henriques PC, Seabra CL, Martins MC. The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection. Expert Rev Anti Infect Ther. 2014;12(8):981–992. doi:10.1586/14787210.2014.930663
   PubMed Web of Science ®Google Scholar
• Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, et al. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta biomaterialia. 2020;114:206–220. doi:10.1016/j.actbio.2020.06.035
   PubMed Web of Science ®Google Scholar
• Cui L, Yao Y, Yim EKF. The effects of surface topography modification on hydrogel properties. APL Bioengineering. 2021;5(3):031509. doi:10.1063/5.0046076
   PubMed Web of Science ®Google Scholar
• Park J, Kim D. Release behavior of amoxicillin from glycol chitosan superporous hydrogels. Journal of Biomaterials Science, Polymer Edition. 2009;20(5–6):853–862. doi:10.1163/156856209X415855
   PubMed Web of Science ®Google Scholar
• Mohamed NA, Abd El-Ghany NA, Abdel-Aziz MM. Synthesis, characterization, anti-inflammatory and anti-Helicobacter pylori activities of novel benzophenone tetracarboxylimide benzoyl thiourea cross-linked chitosan hydrogels. Int J Biol Macromol. 2021;181:420–429. doi:10.1016/j.ijbiomac.2021.04.095
   Web of Science ®Google Scholar
• Moogooee M, Ramezanzadeh H, Jasoori S, Omidi Y, Davaran S. Synthesis and in vitro studies of cross-linked hydrogel nanoparticles containing amoxicillin. J Pharm Sci. 2011;100(3):1353–1367. doi:10.1002/jps.22351
   Web of Science ®Google Scholar
• El-Mahrouk GM, Aboul-Einien MH, Makhlouf AID. Design, optimization, and evaluation of a novel metronidazole-loaded gastro-retentive pH-Sensitive Hydrogel. AAPS PharmSciTech. 2016;17(6):1285–1297. doi:10.1208/s12249-015-0467-x
   PubMed Web of Science ®Google Scholar
• Chang C-H, Lin Y-H, Yeh C-L, Chen Y-C, Chiou S-F, Hsu Y-M, Chen Y-S, Wang -C-C. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori. Biomacromolecules. 2010;11(1):133–142. doi:10.1021/bm900985h
   PubMed Web of Science ®Google Scholar
• Silva K, de Carvalho DÉL, Valente VMM, Campos Rubio JC, Faria PE, Silva-Caldeira PP. Concomitant and controlled release of furazolidone and bismuth(III) incorporated in a cross-linked sodium alginate-carboxymethyl cellulose hydrogel. Int J Biol Macromol. 2019;126:359–366. doi:10.1016/j.ijbiomac.2018.12.136
   PubMed Web of Science ®Google Scholar
• Merino S, Martín C, Kostarelos K, Prato M, Vázquez E. Nanocomposite hydrogels: 3D polymer-nanoparticle synergies for on-demand drug delivery. ACS nano. 2015;9:4686–4697.
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen X, Yuk H, Lin S, Liu X, Parada G. Soft materials by design: unconventional polymer networks give extreme properties. Chem Rev. 2021;121:4309–4372.
   PubMed Web of Science ®Google Scholar
• Narayanaswamy R, Torchilin VP. Hydrogels and their applications in targeted drug delivery. Molecules. 2019;24(3):603
   PubMed Web of Science ®Google Scholar
• Huang P, Wang X, Liang X, Yang J, Zhang C, KongWang D, Wang W. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta biomaterialia. 2019;85:1–26. doi:10.1016/j.actbio.2018.12.028. PMCID: 30579043.
   PubMed Web of Science ®Google Scholar